| Literature DB >> 28794394 |
Norihiro Kobayashi1, Hiroto Izumi2, Yasuo Morimoto2.
Abstract
OBJECTIVE: We reviewed studies on pulmonary, reproductive, and developmental toxicity caused by carbon nanotubes (CNTs). In paricular, we analyzed how CNT exposure affects the several processes of pulmonary toxicity, including inflammation, injury, fibrosis, and pulmonary tumors.Entities:
Keywords: Carbon nanotube; Inhalation; Intratracheal instillation; Pulmonary toxicity; Reproductive toxicity
Mesh:
Substances:
Year: 2017 PMID: 28794394 PMCID: PMC5635148 DOI: 10.1539/joh.17-0089-RA
Source DB: PubMed Journal: J Occup Health ISSN: 1341-9145 Impact factor: 2.708
Summary of pulmonary toxicity studies on CNTs
| Exposure route | CNT type | Characterization | Animal | Concentration /dose | Post-exposure observation period | Findings | References |
|---|---|---|---|---|---|---|---|
| Inhalation | MWCNTs (mixture of MWCNTs and graphitic nanofibres) | Size: 10-20 nm×5-15 μm Impurities: 0.5% Ni and Fe Surface area: 100 m2/g MMAD: 700-1000 nm/1800 nm | Male C57BL/6 mouse | 0.3, 1, 5.3 mg/m3, 7 and 14 days, 6 h/day | 0 day | No local pulmonary effects. Non-monotonic systemic immune suppression | Mitchell et al. (2007)11) |
| 0.3, 1 mg/m3, 14 days; 6 h/day | 0 day | Systemic immune suppression, not due to systemic uptake of MWCNT, but due to release of immune suppressing signals from the lung | Mitchell et al. (2009)12) | ||||
| Inhalation | MWCNTs | Size: 5-15 nm×0.1-10 μm Impurities: 10% metal oxide Surface area: 250-300 m2/g MMAD: 0.5-1.3 μm | Wistar rat | 2, 8, 32 mg/m3, 5 days, 6 h/day | 3, 24 day | Increase in BALF total cell counts, protein content, enzyme activities | Ma-Hock et al. (2009)13) |
| Inhalation | MWCNT | Co 0.46-0.53% BET 253 m2/g Range of length: 200-300nm | Wistar rat male, female | 0.1, 0.4, 1.5, 6 mg/m3, 13 week | 6 months | Inflammation at 0.4 mg/m3 (transient) | Pauluhn (2010)14) |
| Inhalation | Carbon nanofiber | Carbon>99.5% Diameter 158 nm Length 5.8 μm BET 13.8 m2/g | SD rat male, female | 0.54 mg/m3 (4.9f/cc) 2.5 mg/m3 (56f/cc) 25 mg/m3 (252f/cc) 13 weeks | 90 days | Persistent inflammation at 25 mg/m3 | DeLorme et al. (2012)15) |
| Inhalation | MWCNT | Diameter 44 nm BET 69 m2/g Fe 0.0005% | Wistar rat male | 0.37 mg/m3 (>70% individual) 4 weeks | 3 months | No inflammation, no fibrosis | Morimoto et al. (2012)16) |
| Inhalation | SWCNT | Diameter 3 nm BET 1064 m2/g Impurities 0.03% | Wistar rat male | 0.03 mg/m3 (5*104/cc) 0.13 mg/m3 (6.6*104/cc) | 3 months | No inflammation, no fibrosis | Morimoto et al. (2012)17) |
| Inhalation | MWCNTs | Size: 94.1-98 nm×5.53-6.19 μm Impurities: >99.6-99.8% purity Surface area: 24-28 m2/g MMAD: 1.4-1.6 μm | Male and female F344 rat | 0, 0.2, 1, 5 mg/m3, 13 weeks 5 days/week 6 h/day | 0 day | Increase in lung weights, BALF inflammatory parameters. | Kasai et al. (2015)18) |
| Intratracheal instillation | SWCNT | nominal diameter 1.4 nm, length >1μm, agglomerated rope ~30 nm | CD rat male | 1 mg/kg, 5 mg/kg | 3 months | Transient inflammation | Warheit et al. (2004)19) |
| Intratracheal instillation | MWCNT | CNT: length 5.9 μm Ground CNT: length 0.7 μm | SD rat female | 0.5, 2, 5 mg/rat | 60 days | Inflammation (until 15 days) and granuloma | Muller et al. (2005)20) |
| Intratracheal instillation | SWCNTs | Size: 1-2 nm×several μm (No exact characterization) | Male ICR mice | 0.5 mg/kg | 3, 14 days | Release of cytokines (NF-κB) | Chou et al. (2008)21) |
| Intranasal instillation | Purified DWCNTs (80% DWCNTs, 20% SWCNTs) | Size: 1.2-3.2 nm×1-10 μm (bundles up to 100 μm) | Male Swiss mice | 1.5 mg/kg | 6, 24, 48 h | Local and systemic inflammation. | Crouzier et al. (2010)22) |
| Intratracheal instillation | MWCNTs | Size: 20-50 nm×0.5-2 μm, Impurities: >95% purity Surface area: 280 m2/g | Male Sprague- Dawley rat | 1, 10, 100 μg/rat | 1, 7, 30, 90, 180 days | No inflammation, apoptosis of macrophages having phagocytosed MWCNTs (elimination) | Elgrabli et al. (2008)23) |
| Intratracheal instillation | MWCNTs | Size: 11-170 nm×5-9 μm Impurities: >90% carbon Surface area: 12.83 m2/g | ICR male mouse | 5, 20, 50 mg/kg | 1, 3, 7, 14 days | Increase in immune cells. | Park et al. (2009)24) |
| Intratracheal instillation | MWCNT | Diameter 88 nm Length 5 μm Fe 0.44% | F344 rat male | 40 μg/rat 160 μg/rat | 91 days | Persistent inflammation and fibrosis | Aiso et al. (2010)25) |
| Intratracheal aspiration | MWCNT | Diameter 31nm Length 20μm BET 50 m2/g Impurity 3.5 wt% | C57BI mice female | 20 μg/mouse 40 μg/mouse | 7 days | Transient inflammation | Han et al. (2010)26) |
| Intratracheal instillation | MWCNTs | Size: 60 nm×1.5 μm Impurities: 99.79% carbon (7-8% carbon soot) Surface area: 23.0 m2/g | Male Sprague- Dawley rat | 0.04, 0.2, 1 mg/kg | 3, 7, 28, 91 days | Increase in BALF neutrophils, eosinophils, LDH, and TP levels increased. | Kobayashi et al. (2010)27) |
| Intratracheal instillation | SWCNTs | Size: 12 nm×0.32 μm Impurities: 0.05% total metal Surface area: 1064 m2/g | Male Sprague- Dawley rat | 0.04, 0.2, 1, 2 mg/kg | 1, 3, 7, 28, 91, 182 days | Increase in BALF neutrophils, macrophages, lymphocytes, eosinophils, LDH, protein, and IL-1β,IL-6. | Kobayashi et al. (2011)28) |
| Intratracheal instillation | MWCNT | Diameter 44 nm BET 69 m2/g Fe 0.0005% | Wistar rat male | 0.66 mg/kg 3.3 mg/kg | 6 months | Inflammation at 0.66mg/kg (transient) 3.3mg/kg (persistent) | Morimoto et al. (2012)16) |
| Intratracheal instillation | SWCNT | Diameter 1.8 nm BET 878 m2/g | Wistar rat male male | 0.66 mg/kg 1.32 mg/kg | 6 months | Persistent inflammation | Morimoto et al. (2012)29) |
| Pharyngeal aspiration | SWCNT | Diameter 1-4nm Length 1-3 μm BET 1040 m2/g | C57BL/6 mice, female | 40 μg/mouse | 28 days | Persistent inflammation and granuloma | Murray et al. (2012)30) |
| Intratracheal | SWCNT | BET 877.7 m2/g Diameter 44 nm | Wistar rat male | 0.2 mg/rat 0.4 mg/rat | 754 days | granuloma (+) → (-) 365 and 754days | Fujita et al. (2015)31) |
| Pharyngeal aspiration | MWCNTs | Size: 49 nm×3.86 μm Impurities: 0.78% total metals | Male C57BL/6J mouse | 10, 20, 40, 80 μg/mouse | 1, 7, 28, 56 days | Increase in BAL PMNs, LDH, albumin. | Porter et al. (2010)32) Mercer et al. (2011)33) |
| Pharyngeal aspiration | Purified SWCNTs | Size: 1-4 nm Impurities: 0 .23% Fe Surface area: 1040 m2/g | Female C57 BL/6 mouse | 0, 10, 20, 40 μg/mouse (0, 0.5, 1, 2 mg/kg) | 1, 3, 7, 28, 60 days | Inflammation (TNF-α and IL-1β increased). | Shvedova et al. (2005)34) |
| Pharyngeal aspiration | Purified SWCNTs | Size: 1-4 nm Impurities: 0.23% Fe Surface area: 1040 m2/g | Female C57 BL/6 mouse | 0, 40 μg/mouse (0, 1.9 mg/kg) | 1, 3, 7, 28 days | Robust, acute inflammation (PMNs, TNF-α,IL-6, LDH increased). | Shvedova et al. (2007)35) |
| Pharyngeal aspiration | SWCNTs | Size: 0.8-1.2 nm×100-1000 nm Impurities: 17.7% Fe Surface area: 508 m2/g | Female C57 BL/6 mouse | 0, 5, 10, 20 μg/mouse (0, 0.25, 0.5, 1 mg/kg) | 1, 3, 7, 28 days | Inflammation (TNF-α,IL-6 and TGF-β increased) GSH depletion, lipid peroxidation, oxidised proteins | Shvedova et al. (2008)36) |
| Pharyngeal aspiration | DWCNT | Diameter 1-2 nm Length<5 μm | C57BL/6 mice male | 1,10,40 μg/mouse | 56 days | Persistent alveolitis and interstitial fibrosis at 10 μg and 40 μg | Sager et al. (2013)37) |
Summary of reproductive and developmental toxicity studies on CNTs in rodents
| Exposure route | CNT type | Characterization | Animals | Exposure day | Dose | Findings | References |
|---|---|---|---|---|---|---|---|
| Iintravenous injection | MWCNT | COOH-MWCNTs (D: 20-30 nm, L: 0.5-2.0 mm); NH4-MWCNTs (D: 20-30 nm, L: 0.5-2.0 mm) in PBS with 0.1% Tween 80 | BALB/c mouse(4-8/group) | Once or every 3 d, 5 times | 5 mg/kg | Transient histopathological changes in the testes after multiple injections of both MWCNTs; transiently increased levels of MDA in the testes after multiple injections of COOH-MWCNTs | Bai et al. (2010)70) |
| Intraperitoneal injection | MWCNT | NM-400, D: 10 nm, L: 295 nm, 5.3% Al, 0.4% Fe, 0.2% Co, highly bent (Nanocyl, Belgium) in water with 2% mouse serum | C57BL/6JBomTac mouse(30/group) | One day preconception | 67 mg/d | Increased lag in delivery of the first litter; long-lasting pathological changes, mononuclear infiltration, and bronchiole sub-epithelial edema in the lungs and an increased number of Kupffer cells and hyperplasia and hypertrophy of Kupffer cells in the liver | Hougaard et al. (2013)71) |
| Intraperitoneal injection | MWCNT | MWNT-7, width: 100 nm, 27.5%4longer than 5 mm (MITSUI, Japan) in 2% CMC-Na solution | CD1 mouse (6-16/group) | GD 9 (vaginal plug¼GD 0) | 2, 3, 4, 5 mg/kg | Increased maternal spleen weight at doses of 2, 3, 4, and 5 mg; resorption rate at 4 and 5 mg; maternal incidence of fetuses with external malformations at 4mg and skeletal malformations at 2mg and higher | Fujitani et al. (2012)72) |
| Intratracheal instillation | MWCNT | GD 9 | 3, 4, 5 mg/kg | Increased maternal lung weight at a dose of 5 mg; dams had fetuses with external and skeletal malformations at 4 and 5 mg | |||
| Intraperitoneal injection | MWCNT | D: 30 nm, L: 10 mm, SSA: 270m2/g, 95% C (Research Institute of Petroleum Industry, Tehran, Iran) in PBS | NMR1 mouse (10/group) | Mating day and GD 3 | 1, 10 mg/d | Increased time in the closed arm of elevated plus-maze and floating period in forced swimming test at a dose of 1mg | Ivani et al. (2012)73) |
| Intraperitoneal injection | MWCNT | PL-PEG-NH4-MWCNT-8 (D: 58 nm, L: 0.5-2 mm); PL-PEG-NH4-MWCNT-20 (D: 20-30 nm, L: 0.5-2 mm); PL-PEG-NH4-MWCNT-50 (D: 50 nm, L: 0.5-2 mm) in water PL-PEG-NH4-MWCNT-50 in water PL-PEG-NH4-MWCNT-50 in water 64Cu-labeled PL-PEG-NH4-MWCNT-8, 20, 50 in water | p53+/- mouse (4-6/group) | GDs 10.5, 12.5, 15.5 DG 10.5 or 15.5 GD 15.5 | 2 mg/kg/d 2 or 5 mg/ kg/d 5 mg/kg | Increase fetal brain defect (50% of p53+/- fetuses) after injection on GD 10.5, fetal brain deformity after injection of PLPEG-NH4-MWCNT-50, nuclear DNA damage in fetal | Huang et al. (2014)74) |
| Intraperitoneal injection | MWCNT | o-MWCNTs (D: 10-30 nm, L: 1-2 mm, purity496%, Shenzehen Nanotech, Shenzehen, China) in saline 99mTc-o-MWCNTs in saline | Kunming mouse (10/group) | GD 7 until abortion or parturition GDs 4, 11, and 15 GDs 9-11 GD 17 | 20 mg/kg/d | Increased abortion rate and estradiol level in maternal sera at GDs 7 and 14, presence of ROS in the placentas of first-time pregnant mice | Qi et al. (2014)75) |
| Oral gavage | MWCNT | CM-95, D: 10-15 nm, L: 20 mm, 95% C, 5% Fe, (Hanwha Nanotech, Seoul, South Korea) in 1% CMC solution | SD rat (12/group) | GDs 6-19 (sperm¼GD 0) | 8, 40, 200, 1000 mg/kg/d | Decreased maternal thymus weight at 1000 mg | Lim et al. (2011)76,77) |
| Oral gavage | MWCNT | COOH-MWCNTs (D inner/outer: 20 nm/30 nm, L: 0.5-2.0 mm) | CD1 mouse (10/group) | GD 0-21 d after delivery (vaginal plug¼GD 0) | 22, 65 mg/ kg/d | No effect on litter size, sex ratio of pups, or body or organ weight, or serum levels of malondialdehyde, FSH, LH, or testosterone of male offspring | Wang et al. (2014)78) |
| Intraperitoneal injection | SWCNT | PEG-SWCNTs (L: 86 nm, low content of metals, carbon solution) in PBS | CD1 mouse (5-18/group) | GD 5.5 (vaginal plug¼GD 0.5) GD 14.5 GDs 5.5, 8.5, 11.5 | 0.1, 10, 30 mg 10 mg 10 mg/d | One fetus with external malformations in 1/10 dams after injection of 30 mg at GD 5,5 and a total of five fetuses with external malformations in 2/10 dams after multiple injections | Campagnolo et al. (2013)79) |
| Intraperitoneal injection | SWCNT | p-SWCNTs; o-SWCNTs; uo-SWCNTs in DMEM containing BSA | CD1 mouse (16-23/group) | GD 5.5 | 0.01, 0.1, 0.3, 3, 30 mg | Maternal incidence of miscarriage at 30 mg of p-, o-, and uo-SWCNTs; Incidence of dams with malformed fetuses after 3 mg of p-SWCNTs, 30 mg of o-SWCNTs, and 0.3 mg of uo-SWCNTs; ROS in malformed fetuses and their placentas for uo-SWCNTs group | Pietroiusti et al. (2011)81) |
| Intraperitoneal injection | SWCNT | PL-PEG-NH4-SWCNTs (D: 1-2 nm, L: 0.5-2 mm) in water 64Cu-labeled PL-PEG-NH4-SWCNTs (functionalization with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino (polyethylene glycol)-2000]) in water | p53+/- mouse (4-6/group) | GDs 10.5, 12.5, 15.5 GD 15.5 | 2 mg/kg/d | No effect on maternal or fetal body weight, or incidence of fetal deformities. | Huang et al. (2014)74) |
| Oral gavage | SWCNT | FOH-SWCNTs (size: 45-138 nm) in 0.5% tragacanth gum solution | CD1 mouse (10-12/group) | GD 9 (vaginal plug¼GD 1) | 10, 100 mg/kg | Incidences of resorptions and fetuses with gross or skeletal anomalies at 10 mg/kg (but not 100 mg/kg) | Philbrook et al. (2011)80) |
| GD, gestation day | |||||||